The newborn screening market size in Europe is expected to be valued at USD 650 million by 2027 from USD 380 million in 2022, growing at a CAGR of 11.34% from 2022 to 2027.
The growing incidence of newborn mortality rates owing to various disorders is one of the major factors propelling the newborn screening market in Europe. According to the data published by World Bank, the mortality rate among infants was 3 in 1000 in 2020 in Europe. The government has taken several measures to reduce these mortality rates, such as necessitating a preliminary screening test to prevent diseases that may occur in their lifetime for newborn babies. In addition, newborn diseases can also be caused due to genetic disorders that may affect the infant during pregnancy.
The increased awareness among parents on taking appropriate care for the health of infants in resulting in the growth of the newborn screening market in the European region. The screening method has been the most helpful process for preventing newborn deaths due to increased awareness about different screening methods and the device's ability to detect any present or future risk of diseases. In addition, with increasing social media and television advertisements, many uneducated people also know about the screening methods that help their children's lives leading to market growth.
Furthermore, technological advancements are anticipated to fuel regional market growth during the forecast period. Technological advances have demanded the expansion of newborn screening devices over the last two decades. Key players are focused on developing these screening methods with advanced technology that does not affect infants with pain or radiation. They also found screening methods by increasing the comfort level of the infants to get an accurate result with some special equipment.
However, the increasing usage of refurbished products for screening is primarily restraining the European newborn screening market growth. Furthermore, most hospitals need investment to buy high-cost equipment and screening devices, which can be challenging to acquire. In addition, the lack of skilled professionals, lack of reimbursement policies, lack of accuracy in the screening result, and lack of awareness about screening devices in rural areas impede the market growth.
This research report on the Europe newborn screening market has been segmented and sub-segmented into the following categories.
By Product:
By Technology:
By Test Type:
By Country:
The European region held the most significant share of the worldwide market in 2021 and is anticipated to hold good occupancy in the global market during the forecast period. The growth of the regional market can be attributed to the increasing newborn screening facilities centers and increasing health care expenditure on the infant's health. In Europe, several newborn screening programs have been conducted, which help to minimize the number of patients suffering from various diseases. Additionally, the NBS programs are well organized by the International Society for Neonatal Screening in the European region. They have the best treatment practice, assisting with planning the confirmatory tests, etc. These programs help in early diagnoses to prevent chronic diseases, increase the quality of life of infants and reduce the mortality rate.
Germany is one of the leading regional markets in Europe and is expected to occupy a considerable share of the European market during the forecast period. Spinal muscular atrophy is a common neurodegenerative disease in childhood that requires early diagnosis and treatment to prevent significant disability. In Germany, the incidence of Spinal muscular atrophy is 1 in every 10,002 live births. Children who are suffering from SMA type 1 are unable to sit. The condition results in death due to respiratory failure in the first two years of life. As a result, newborn screening devices have had high market growth in recent years in this area.
On the other hand, the UK market is predicted to grow at a healthy CAGR in the coming years. Cystic fibrosis (CF) is a severe inherited condition seen in children in nearly one in 2500 babies born in the UK. Children in this region are diagnosed within the first few weeks of life through newborn bloodspot screening to reduce the problematic situation. In addition, the UK Government launched a Newborn Genomes Programme in the year 2022, which helps to detect rare genome sequencing to detect rare diseases in newborn babies. Due to all these rare diseases in the United Kingdom, nearly one-third of children die before their fifth birthday, leading to market growth.
KEY MARKET PLAYERS:
AB Sciex LLC, Waters Corp., Trivitron Healthcare, GE Healthcare, Masimo Corp., PerkinElmer Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Natus Medical Inc., and Covidien Plc are some of the noteworthy companies in the European newborn screening market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region